<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00105482</url>
  </required_header>
  <id_info>
    <org_study_id>NIAAAOMA15632</org_study_id>
    <secondary_id>P50AA015632</secondary_id>
    <secondary_id>9P50AA015632</secondary_id>
    <nct_id>NCT00105482</nct_id>
  </id_info>
  <brief_title>Targeted Interventions for Weight-Concerned Smokers</brief_title>
  <official_title>Testing the Effectiveness of Low Dose Naltrexone for Smoking Cessation and Minimization of Post-cessation Weight Gain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Weight gain after quitting smoking is an important barrier to treatment for many smokers.
      This study will test a drug called naltrexone with weight-concerned smokers to investigate
      whether or not this drug both improves smoking cessation quit rates and minimizes post quit
      weight gain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 6-month randomized, double-blind, placebo controlled trial of 25 mg naltrexone for
      smoking cessation in a sample of 270 male and female weight-concerned smokers. Participants
      also receive transdermal nicotine replacement therapy during the first 8 weeks of the study,
      which they begin on their quit date. Naltrexone study medication will be started a week
      before their quit date and continued through the six-month period. Brief behavioral
      counseling and research assessments are provided for two sessions prior to the quit date and
      then weekly for two weeks, bi-weekly for a month and every four weeks thereafter. A follow-up
      appointment is completed at 12 months after participants' quit date.

      The primary outcomes are six-month point prevalence abstinence and post-cessation weight gain
      for those who are continuously abstinent (not even a puff).

      Secondary outcomes include an examination of alcohol consumption, evaluation of urges, other
      measures of smoking cessation success, point prevalence abstinence at 12 months, and food
      preferences. A number of tertiary measures will be obtained for examining predictors of
      smoking cessation, weight gain, and naltrexone response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weight Gain at 26 Weeks.</measure>
    <time_frame>26 weeks</time_frame>
    <description>Weight change from baseline measured at 26 weeks.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Point Prevalence Smoking Abstinence at 26 Weeks.</measure>
    <time_frame>26 weeks</time_frame>
    <description>The number of people that were abstinent from cigarette smoking at 26 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Weight Gain at 6 Weeks.</measure>
    <time_frame>6 weeks</time_frame>
    <description>Weight change from baseline measured at 6 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Point Prevalence Smoking Abstinence at 6 Weeks</measure>
    <time_frame>6 weeks</time_frame>
    <description>The number of people that were abstinent from cigarette smoking at 6 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cigarettes Smoked Per Day.</measure>
    <time_frame>26 weeks</time_frame>
    <description>Average number of cigarettes smoked per day at 26 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Naltrexone, Transdermal Nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arm 1 (Experimental) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Naltrexone 25 mg oral capsule once per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Naltrexone, Transdermal Nicotine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Arm 2 (Placebo Comparator) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Placebo Naltrexone 25 mg oral capsule once per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naltrexone</intervention_name>
    <description>Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks</description>
    <arm_group_label>Naltrexone, Transdermal Nicotine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal nicotine replacement</intervention_name>
    <description>Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day</description>
    <arm_group_label>Naltrexone, Transdermal Nicotine</arm_group_label>
    <arm_group_label>Placebo Naltrexone, Transdermal Nicotine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral counseling</intervention_name>
    <description>Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
    <arm_group_label>Naltrexone, Transdermal Nicotine</arm_group_label>
    <arm_group_label>Placebo Naltrexone, Transdermal Nicotine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Concern about gaining weight after quitting. This will be assessed using
             questionnaires that will provide a rating system to determine qualified participants.

          -  2. Age 18 and older.

          -  3. Willingness and ability to give written consent.

          -  4. Smoking greater than 10 cigarettes per day for at least 1 year.

          -  5. At least one prior attempt to stop smoking.

          -  6. Baseline expired carbon-monoxide level of at least 10 ppm.

          -  7. Weigh at least 100 lbs.

          -  8. English speaking.

          -  9. One person per household.

        Exclusion Criteria:

          -  1. Pregnant or nursing women or women attempting to conceive.

          -  2. Unstable cardiac disease.

          -  3. History of dermatoses.

          -  4. Current alcohol or drug dependence other than nicotine dependence.

          -  5. Serious current neurologic, psychiatric or medical illness, including those with a
             significant risk of committing suicide based on history or investigator's judgment.

          -  6. Chronic pain conditions necessitating opioid treatment (naltrexone, an opioid
             antagonist, will make these medications ineffective).

          -  7. History of cirrhosis or significant hepatocellular injury as evidenced by SGOT or
             SGPT &gt;3 x normal or elevated bilirubin.

          -  8. Current use of smokeless tobacco, pipes, cigars, nicotine gum, patch, nasal spray,
             inhaler, or lozenges.

          -  9. Patients requiring concomitant therapy with any psychotropic drug or on any drug
             with a psychotropic component except those who are on a stable dose of an Selective
             Serotonin Reuptake Inhibitor for at least two months for the indications of Major
             Depressive Disorder, Premenstrual Syndrome (PMS) or Premenstrual Dysphoric Disorder
             (PMDD).

          -  10. Subjects with a positive opiate urine drug screen will be excluded to avoid
             precipitating opiate withdrawal.

          -  11. Current use of opiates.

          -  12. Currently on a medically prescribed diet.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie O'Malley, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine Substance Abuse Treatment Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.quitwithyale.org</url>
    <description>This website describes the Transdisciplinary Tobacco Use Research Center at Yale University. Click here for more information about the study: Targeted Interventions for Weight-concerned Smokers.</description>
  </link>
  <results_reference>
    <citation>Toll BA, White M, Wu R, Meandzija B, Jatlow P, Makuch R, O'Malley SS. Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial. Drug Alcohol Depend. 2010 Oct 1;111(3):200-6. doi: 10.1016/j.drugalcdep.2010.04.015. Epub 2010 Jun 12.</citation>
    <PMID>20542391</PMID>
  </results_reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2005</study_first_submitted>
  <study_first_submitted_qc>March 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2005</study_first_posted>
  <results_first_submitted>January 28, 2013</results_first_submitted>
  <results_first_submitted_qc>January 28, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 5, 2013</results_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tobacco</keyword>
  <keyword>Smoking</keyword>
  <keyword>Weight</keyword>
  <keyword>Weight perception</keyword>
  <keyword>Naltrexone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Naltrexone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Naltrexone</title>
          <description>Arm 1 (Experimental) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Naltrexone 25 mg oral capsule once per day
Transdermal nicotine replacement : Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
Naltrexone : Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Arm 2 (Placebo Comparator) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Placebo Naltrexone 25 mg oral capsule once per day
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="87"/>
                <participants group_id="P2" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost Interest</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Scheduling Conflict</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn by PI</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Naltrexone</title>
          <description>Arm 1 (Experimental) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Naltrexone 25 mg oral capsule once per day
Transdermal nicotine replacement : Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
Naltrexone : Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Arm 2 (Placebo Comparator) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Placebo Naltrexone 25 mg oral capsule once per day
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="87"/>
            <count group_id="B2" value="85"/>
            <count group_id="B3" value="172"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.2" spread="10.0"/>
                    <measurement group_id="B2" value="45.5" spread="11.3"/>
                    <measurement group_id="B3" value="44.4" spread="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Weight Gain at 26 Weeks.</title>
        <description>Weight change from baseline measured at 26 weeks.</description>
        <time_frame>26 weeks</time_frame>
        <population>All patients who were randomized comprised the primary ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone</title>
            <description>Arm 1 (Experimental) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Naltrexone 25 mg oral capsule once per day
Transdermal nicotine replacement : Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
Naltrexone : Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Arm 2 (Placebo Comparator) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Placebo Naltrexone 25 mg oral capsule once per day
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Gain at 26 Weeks.</title>
          <description>Weight change from baseline measured at 26 weeks.</description>
          <population>All patients who were randomized comprised the primary ITT population.</population>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.75" spread="8.94"/>
                    <measurement group_id="O2" value="9.71" spread="9.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Point Prevalence Smoking Abstinence at 26 Weeks.</title>
        <description>The number of people that were abstinent from cigarette smoking at 26 weeks.</description>
        <time_frame>26 weeks</time_frame>
        <population>All patients who were randomized comprised the primary ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone</title>
            <description>Arm 1 (Experimental) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Naltrexone 25 mg oral capsule once per day
Transdermal nicotine replacement : Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
Naltrexone : Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Arm 2 (Placebo Comparator) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Placebo Naltrexone 25 mg oral capsule once per day
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Point Prevalence Smoking Abstinence at 26 Weeks.</title>
          <description>The number of people that were abstinent from cigarette smoking at 26 weeks.</description>
          <population>All patients who were randomized comprised the primary ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Gain at 6 Weeks.</title>
        <description>Weight change from baseline measured at 6 weeks.</description>
        <time_frame>6 weeks</time_frame>
        <population>All patients who were randomized comprised the primary ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone</title>
            <description>Arm 1 (Experimental) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Naltrexone 25 mg oral capsule once per day
Transdermal nicotine replacement : Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
Naltrexone : Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Arm 2 (Placebo Comparator) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Placebo Naltrexone 25 mg oral capsule once per day
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Gain at 6 Weeks.</title>
          <description>Weight change from baseline measured at 6 weeks.</description>
          <population>All patients who were randomized comprised the primary ITT population.</population>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="4.58"/>
                    <measurement group_id="O2" value="2.19" spread="4.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Point Prevalence Smoking Abstinence at 6 Weeks</title>
        <description>The number of people that were abstinent from cigarette smoking at 6 weeks.</description>
        <time_frame>6 weeks</time_frame>
        <population>All patients who were randomized comprised the primary ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone</title>
            <description>Arm 1 (Experimental) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Naltrexone 25 mg oral capsule once per day
Transdermal nicotine replacement : Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
Naltrexone : Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Arm 2 (Placebo Comparator) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Placebo Naltrexone 25 mg oral capsule once per day
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Point Prevalence Smoking Abstinence at 6 Weeks</title>
          <description>The number of people that were abstinent from cigarette smoking at 6 weeks.</description>
          <population>All patients who were randomized comprised the primary ITT population.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="87"/>
                <count group_id="O2" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cigarettes Smoked Per Day.</title>
        <description>Average number of cigarettes smoked per day at 26 weeks.</description>
        <time_frame>26 weeks</time_frame>
        <population>Patients were analyzed per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Naltrexone</title>
            <description>Arm 1 (Experimental) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Naltrexone 25 mg oral capsule once per day
Transdermal nicotine replacement : Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
Naltrexone : Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Arm 2 (Placebo Comparator) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Placebo Naltrexone 25 mg oral capsule once per day
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
          </group>
        </group_list>
        <measure>
          <title>Cigarettes Smoked Per Day.</title>
          <description>Average number of cigarettes smoked per day at 26 weeks.</description>
          <population>Patients were analyzed per protocol.</population>
          <units>number of cigarettes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.10" spread="8.43"/>
                    <measurement group_id="O2" value="7.85" spread="8.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>26 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Naltrexone</title>
          <description>Arm 1 (Experimental) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Naltrexone 25 mg oral capsule once per day
Transdermal nicotine replacement : Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
Naltrexone : Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Arm 2 (Placebo Comparator) = Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + Placebo Naltrexone 25 mg oral capsule once per day
Behavioral counseling : Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal EKG</sub_title>
                <description>Abnormal EKG leading to hospitalization.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Finger Laceration</sub_title>
                <description>Patient accidentally cut their finger with a saw, injury resulted in hospitalization.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Thyroid Cancer</sub_title>
                <description>Patient was diagnosed with Thyroid Cancer.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <description>Anxiety leading to hospitalization.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="87"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Rapid Heartbeat</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="87"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="87"/>
                <counts group_id="E2" events="21" subjects_affected="21" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="29" subjects_affected="29" subjects_at_risk="87"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Increased Bowel Freq</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="87"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="87"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="87"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="30" subjects_affected="30" subjects_at_risk="87"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="87"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="40" subjects_affected="40" subjects_at_risk="87"/>
                <counts group_id="E2" events="37" subjects_affected="37" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Change in Libido</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="87"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <counts group_id="E1" events="33" subjects_affected="33" subjects_at_risk="87"/>
                <counts group_id="E2" events="23" subjects_affected="23" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="87"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="87"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Increased Appetite</sub_title>
                <counts group_id="E1" events="43" subjects_affected="43" subjects_at_risk="87"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="87"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="87"/>
                <counts group_id="E2" events="36" subjects_affected="36" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="39" subjects_affected="39" subjects_at_risk="87"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="87"/>
                <counts group_id="E2" events="31" subjects_affected="31" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vivid Dreams</sub_title>
                <counts group_id="E1" events="51" subjects_affected="51" subjects_at_risk="87"/>
                <counts group_id="E2" events="51" subjects_affected="51" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Missed Period</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="31" subjects_affected="31" subjects_at_risk="87"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="87"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephanie Samples O'Malley PhD, Director, Division of Substance Abuse Research</name_or_title>
      <organization>Yale School of Medicine, Department of Psychiatry</organization>
      <phone>(203) 974-7590</phone>
      <email>stephanie.omalley@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

